Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620488 | 0.94 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL11249373 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL16320909 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL7443020 | 0.75 | ADH5 (0.54) | SMN1; SMN2ALDH1A1KDM4EFBP1HSP90AA1 | |
| SCHEMBL676377 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL9363173 | 0.74 | KDM4E (0.60) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL5663652 | 0.74 | KDM4E (0.60) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL82347 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL4343120 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL4573337 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1KDM4ECYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888007-B1 | BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9540364-B2 | Benzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20150218149-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2888007-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014202580-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014031441-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218149-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | PRKAG2, AK2, PRKAB2 | SMN1; SMN2 4709/4885ALDH1A1 1193/4885KDM4E 1764/4885 |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | AK2, PRKAA2, PRKAA1 | SMN1; SMN2 4154/4885ALDH1A1 358/4885KDM4E 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.